Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Momenta Pharma (MNTA)

Momenta Pharma (MNTA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Momenta (MNTA) Up 10% Since Last Earnings Report: Can It Continue?

Momenta (MNTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MNTA : 13.95 (+1.38%)
Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss

Momenta (MNTA) reports a wider loss and misses on sales in Q2 .

MYL : 21.80 (+0.51%)
MNTA : 13.95 (+1.38%)
ABBV : 70.41 (-0.14%)
REGN : 284.87 (+1.15%)
Momenta Pharmaceuticals (MNTA) Reports Q2 Loss, Misses Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -176.19% and -43.03%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

MNTA : 13.95 (+1.38%)
Momenta: 2Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Friday reported a loss of $114 million in its second quarter.

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals Reports Second Quarter 2019 Financial and Operating Results

-- Launches adaptive Phase 2/3 study of nipocalimab (M281) in Warm Autoimmune Hemolytic Anemia (wAIHA), the Company's third study of its FcRn inhibitor; top-line data expected by end of 2021 --

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals Launches Phase 2/3 Trial of M281 for the Treatment of Warm Autoimmune Hemolytic Anemia and is Granted FDA Fast Track Designation

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, announced the launch of an...

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals Announces Fast Track Designation for M281 (nipocalimab) in Hemolytic Disease of the Fetus and Newborn (HDFN)

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that the...

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals (MNTA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Momenta (MNTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals Announces Date of Second Quarter 2019 Financial Results Conference Call and Webcast

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that it will...

MNTA : 13.95 (+1.38%)
Momenta Pharmace Down 16.7% Since SmarTrend Downtrend Call (MNTA)

SmarTrend identified a Downtrend for Momenta Pharmace (NASDAQ:MNTA) on May 28th, 2019 at $12.14. In approximately 2 months, Momenta Pharmace has returned 16.72% as of today's recent price of $10.11.

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals to Webcast Presentation at the 2019 Bank of America Merrill Lynch Healthcare Conference

Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced that Craig...

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals (MNTA) Reports Q1 Loss, Misses Revenue Estimates

Momenta (MNTA) delivered earnings and revenue surprises of -2.22% and -57.08%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

MNTA : 13.95 (+1.38%)
Momenta: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Thursday reported a loss of $44.8 million in its first quarter.

MNTA : 13.95 (+1.38%)
Momenta Pharmaceuticals Reports First Quarter 2019 Financial and Operating Results

-- M281 Phase 2 trials in MG and HDFN active and enrolling patients --

MNTA : 13.95 (+1.38%)
Momenta Pharmace Shares Up 16.6% Since SmarTrend's Buy Recommendation (MNTA)

SmarTrend identified an Uptrend for Momenta Pharmace (NASDAQ:MNTA) on February 12th, 2019 at $12.83. In approximately 2 months, Momenta Pharmace has returned 16.60% as of today's recent price of $14.96....

MNTA : 13.95 (+1.38%)
Top 5 Companies in the Biotechnology Industry with the Best Relative Performance (MNTA , SGEN , STML , NVTA , EPZM )

We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...

STML : 11.00 (+1.95%)
MNTA : 13.95 (+1.38%)
SGEN : 71.38 (+1.06%)
Look for Shares of Momenta Pharmace to Potentially Pullback after Yesterday's 3.23% Rise

Momenta Pharmace (NASDAQ:MNTA) traded in a range yesterday that spanned from a low of $14.18 to a high of $14.75. Yesterday, the shares gained 3.2%, which took the trading range above the 3-day high...

MNTA : 13.95 (+1.38%)
New Research Coverage Highlights American International Group, Fox Factory Holding, Momenta Pharmaceuticals, Mercer International, Endurance International Group, and Addus HomeCare -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of American International Group, Inc....

FOXF : 68.10 (+0.52%)
EIGI : 5.18 (-8.96%)
MNTA : 13.95 (+1.38%)
MERC : 13.36 (+0.98%)
AIG : 56.50 (-1.38%)
ADUS : 78.39 (+0.37%)
Momenta Pharmaceuticals Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company focused on discovering and developing novel biologic therapeutics to treat rare immune-mediated diseases, today announced the selection...

MNTA : 13.95 (+1.38%)
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent

Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.

NVS : 86.84 (-0.17%)
MNTA : 13.95 (+1.38%)
TEVA : 8.01 (+0.88%)
BIIB : 238.60 (+0.83%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
AIZ +0.47 , WELL +0.42 , SBAC +0.16 , CCI +0.10 , SO -0.14
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar